Abstract
Background Fasting has long been a ritual or practice in varied religions, and recently, has been noticed to reduce the risk factors of metabolic diseases. In China, varied populations performed a traditional Taoism fasting practice, which lasted for 21-day with <5% calorie intake. However, the safety and applicability of this procedure haven not been investigated.
Methods A total of 144 volunteered participants in six camps following the 21-day fasting (with <5% of normal diet) were investigated. 124 were examined for physical biomarkers and 53 of which also had biochemical markers. Another open label, non-comparative, phase 1/2 prospective cohort study enrolling 20 participants with metabolic diseases was also performed. The physical indices and biochemical biomarkers were collected at varied point of the fasting procedure. Statistical comparison and metagenomic analysis were performed. This study was registered in ClinicalTrials.gov (NCT03193177).
Findings Our preliminary retrospective cohort study showed that no severe adverse event (grade 3 or above) was reported, and all biomarkers fluctuated within the safe ranges, except for the urea acid. The 21-day fasting could significantly reduce BMI and blood pressures. The prospective cohort study of the metabolic diseased participants showed a significant reduction of BMI (3.3±1.0) and systolic blood pressure (28.7±17.8 mmHg) after the fasting procedure. The data also presented significant ameliorations on overweight (16/16), hypertension (11/11) and fatty liver (9/9).
Interpretation The 21-day fasting appeared safe and feasible for both healthy and unhealthy people. It could ameliorate the risk factors associated with hypertension and hyperlipidemia.
Funding This work was supported by National Natural Science Foundation of China and China Overseas-Educated Scholars Development Foundation.
Evidence before this study Fasting has long been a ritual or practice in varied religions. In modern science, it has been noticed that fasting or calorie-restricted diets could benefit for the prevention or treatment of metabolic disorder-associated diseases. In China, the fasting practice, called “Bigu” (literally: avoiding grains), is believed to be capable of prolonging life in Taoism and was also used for medical cure. Compared to the reported fasting practices, the Bigu regimen is a more restricted abstinence, in which the practicers usually experience a continuous 21-day practice with an extremely low-calorie intake (<5% of normal diet). In a rough estimation, there are dozens of Bigu practice camps and over ten thousand practicers per year in China. However, nearly all Bigu camps followed the traditional Taoist procedures but lacked medical and scientific evaluation, which made those practices either mysterious or superstitious to the public.
Added value of this study Our data showed that no severe adverse event was reported during the 21-day fasting procedure, and all biomarkers fluctuated within the safe ranges, except for the urea acid. The 21-day fasting could significantly reduce BMI and blood pressures. The data also presented significant ameliorations on overweight, hypertension and fatty liver. This 21-day fasting appeared safe and feasible for both healthy and unhealthy people. It could ameliorate the risk factors associated with hypertension and hyperlipidemia.
Implications of all the available evidence This preliminary cohort study showed that the long-term extreme fasting was safety to most people and exhibited promising therapeutic effects to hypertension, hyperlipidemia and fatty liver. However, a large cohort study of health-improving effects by long-term extreme fasting is needed.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03193177
Funding Statement
The study was supported by National Natural Science Foundation of China (numbers 81571532, 81771687 and 81601429). MZ was supported by the China Overseas-Educated Scholars Development Foundation. DL was supported by the National Program for Support of Top-notch Young Professionals.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data have already been attached in supplementary dataset and the raw data can be accessible once requested.
